Acrivon Therapeutics Taps Business Development Veteran Levin as CBO — Acrivon Therapeutics, Inc.

Event summary

Michaela Levin, Ph.D., joins Acrivon Therapeutics as Chief Business Officer on August 31, 2026.
Levin brings extensive experience in biotechnology business development, including roles at Recursion, Editas Medicine, and Ovid Therapeutics.
Acrivon granted Levin 130,000 stock options and 30,000 restricted stock units as part of her inducement package.
Levin's previous deal experience includes a $1.7 billion acquisition by MorphoSys AG and multiple strategic licensing agreements.

The big picture

Acrivon Therapeutics is bolstering its business development capabilities with the appointment of Michaela Levin, a seasoned executive with a proven track record in structuring and executing value-creating transactions. This move comes as the company advances its AI-driven AP3 platform and pipeline programs, aiming to maximize the platform's potential through strategic collaborations. Levin's extensive network and transactional experience could be pivotal in navigating the competitive biotechnology landscape and securing partnerships that drive growth.

What we're watching

Strategic Partnerships: How Levin's industry relationships will accelerate Acrivon's business development and partnering efforts.
Pipeline Development: Whether Acrivon can leverage Levin's experience to secure high-value licensing deals for its AP3 platform and pipeline programs.
Execution Risk: The pace at which Acrivon can translate Levin's dealmaking expertise into tangible value for its shareholders.